№ files_lp_4_process_3_073133
File format: docx
Character count: 28728
File size: 155 KB
Note:
Year
Subject:
Narcotic Drugs
Document type:
Form
Organization:
International Narcotics Control Board
Author:
International Narcotics Control Board
Target audience:
Governments of countries and territories
Period of validity:
Annually
Contextual description:
A statistical form used to report data on the production, consumption, and seizures of narcotic drugs by governments.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / City:
Vienna
Subject:
Drug addiction and illegal drug trafficking
Document Type:
Report
Organization / Institution:
Ministry of Internal Affairs of the Republic of Armenia
Author:
Deputy Minister of Internal Affairs of the Republic of Armenia
Target Audience:
International partners, UNODC, civil society
Period of validity:
Until 2025
Approval Date:
November 2024
Date of changes:
November 2024
Organization:
International Narcotics Control Board
Related instrument:
Single Convention on Narcotic Drugs of 1961
Note:
Related instrument
1972 Protocol amending the Single Convention on Narcotic Drugs of 1961
Document type:
Statistical reporting form
Scope:
Production, manufacture, consumption, utilization, stocks and seizures of narcotic drugs
Addressee:
Governments of countries or territories
Reporting deadline:
Not later than 30 June of the year following the reporting year
Reporting period:
Calendar year
Submission address:
Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria
Contact email:
[email protected]
Website:
http://www.incb.org/
Structure:
Part I (Manufacture, consumption, utilization and stocks); Part II (Utilization for manufacture of other substances); Part III (Licit cultivation and production of plant-based narcotic materials); Part IV (Seizures of narcotic drugs and pharmaceutical products)
Measurement units:
Kilograms and grams; for certain substances grams and milligrams
Reference document:
List of Narcotic Drugs under International Control (“Yellow List”)
Year:
1967
Region / City:
Australia
Topic:
Narcotic Drugs Legislation
Document Type:
Act
Authority / Institution:
Australian Government
Author:
Australian Parliament
Target Audience:
Legal professionals, government bodies, and stakeholders in drug regulation
Effective Period:
Ongoing
Approval Date:
1967
Amendment Date:
14 October 2024
Year:
2026
Region / City:
United Kingdom
Subject:
Epilepsy Care, Healthcare Quality Improvement, Clinical Audits
Document Type:
Clinical Audit Specification
Organ / Institution:
Healthcare Quality Improvement Partnership (HQIP)
Author:
Not specified
Target Audience:
Healthcare providers, clinicians, policymakers, patients, and the public
Period of Effectiveness:
Ongoing
Approval Date:
Not specified
Date of Amendments:
Not specified
Organization:
International Narcotics Control Board
Related instrument:
Single Convention on Narcotic Drugs of 1961
Note:
Related instrument
1972 Protocol amending the Single Convention on Narcotic Drugs of 1961
Document type:
Statistical reporting form
Scope:
Production, manufacture, consumption, utilization, stocks and seizures of narcotic drugs
Addressee:
Governments of countries or territories
Reporting deadline:
Not later than 30 June of the year following the reporting year
Reporting period:
Calendar year
Submission address:
Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria
Contact email:
[email protected]
Website:
http://www.incb.org/
Structure:
Part I (Manufacture, consumption, utilization and stocks); Part II (Utilization for manufacture of other substances); Part III (Licit cultivation and production of plant-based narcotic materials); Part IV (Seizures of narcotic drugs and pharmaceutical products)
Measurement units:
Kilograms and grams; for certain substances grams and milligrams
Reference document:
List of Narcotic Drugs under International Control (“Yellow List”)
Year:
2026
Region / City:
Not specified
Topic:
Pediatric Hematology, Neurotoxicity
Document Type:
Case Report
Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals
Patient Age:
6–14 years
Diagnosis:
Relapsed B-cell Acute Lymphoblastic Leukemia (B-ALL)
Treatment Protocols:
MRC-11, BFM 2002
Drug:
High-Dose Methotrexate (HDMTX), Intrathecal Methotrexate (ITMTX), Levetiracetam, Diazepam
Clinical Events:
Generalised tonic-clonic seizures, neurotoxicity
Outcome:
Successful continuation of HDMTX and ITMTX without further seizures
Follow-up Duration:
2 years 3 months of anti-convulsant therapy
Imaging Findings:
Normal brain MRI, hepatosplenomegaly on abdominal ultrasound
Laboratory Findings:
Bone marrow immunophenotyping and cytogenetics detailed in report
Risk Stratification:
Intermediate
Year:
2024
Organization:
National Institute for Health and Care Excellence (NICE)
Document type:
Appeal hearing decision
Subject:
Fenfluramine treatment for Lennox–Gastaut syndrome
Participants:
UCB Pharma, Royal College of Physicians, Tuberous Sclerosis Association, NICE appraisal committee
Location:
United Kingdom
Target audience:
NHS, healthcare professionals, stakeholders involved in rare epilepsy treatment
Hearing date:
6 September 2024
Panel chair:
Professor Jon Cohen
Legal adviser:
Amy Smith, DAC Beachcroft LLP
Evaluation scope:
Assessment of clinical and cost effectiveness for fenfluramine in patients aged 2 years and older
Year:
2012
Edition:
First Edition
Region / State:
Minnesota, United States
Subject:
Motor vehicle stops, warrantless searches, seizures, Fourth Amendment law
Document Type:
Legal handbook / judicial training manual
Author:
Hon. Alan F. Pendleton
Author Position:
Tenth Judicial District Court Judge, State of Minnesota
Institutional Context:
Tenth Judicial District Court, State of Minnesota
Research Assistants:
Michelle Margoles; Ian Mitchell; Chelsey Abrahamson (University of Minnesota Externs)
Manuscript Review and Editing:
Lisa M. Damhof; Abby M. Novak; Kevin Toskey; Abigail Wucherer
Publication Date:
August 2012
Publisher / Issuing Authority:
Hon. Alan F. Pendleton
Place of Publication:
Anoka County Courthouse, Anoka, Minnesota, United States
Address:
325 East Main Street, Anoka, Minnesota 55303
Contact:
Telephone (763) 422-7309; [email protected]
Legal Framework:
Minnesota case law and United States federal case law
Primary Legal Topic:
Exceptions to the Fourth Amendment warrant requirement in motor vehicle searches
Intended Audience:
Judges, attorneys, law enforcement officers, criminal justice trainees
Associated Training Material:
Judicial training video “Motor Vehicles: Stops, Warrantless Searches, Seizures”
Training Format:
Instructional handbook used with video-based criminal justice training sessions
Estimated Training Duration:
Approximately four to six hours
Content Structure:
Chapters, sections, legal explanations, and hypothetical scenarios (vignettes) with numbered questions and answers
Copyright:
All rights reserved by Hon. Alan F. Pendleton
Language:
English
Year:
2003–2015
Country:
South Korea
Topic:
Pharmacoepidemiology, Seizure risk
Document type:
Research article
Institution:
Sungkyunkwan University; Jeonbuk National University; Samsung Advanced Institute for Health Sciences & Technology
Authors:
Sohee Park, Hyesung Lee, Ju Hwan Kim, Ha-Lim Jeon, Ju-Young Shin
Target audience:
Medical researchers, clinicians
Study design:
Case-case-time-control study
Population:
Patients diagnosed with seizures and prescribed tramadol
Sample size:
2,523 incident cases
Data source:
National Health Insurance Service–National Sample Cohort (NHIS-NSC)
Exposure:
Tramadol use
Outcome:
Incidence of seizures
Analysis:
Adjusted odds ratio, dose-response
Key period:
1–30 days risk period, 61–90 and 91–120 days reference periods
Corresponding author:
Ju-Young Shin, PhD
Email:
[email protected]
Publication type:
Peer-reviewed journal article